{"id":"W2061337936","doi":"10.1200/jco.2013.54.2456","title":"Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30<sup>+</sup> Peripheral T-Cell Lymphomas: Results of a Phase I Study","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":true,"ca_institutions":"Seagen (Canada)","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Takeda Oncology","keywords":"Medicine; Brentuximab vedotin; Internal medicine; Neutropenia; Vincristine; CHOP; Anaplastic large-cell lymphoma; Febrile neutropenia; Adverse effect; Gastroenterology; Phases of clinical research; Oncology; Surgery; Cyclophosphamide; Lymphoma; Chemotherapy; CD30","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001124392,0.0006568399,0.0009304903,0.0001801963,0.0002076569,0.000558182,0.0004741387,0.0005538068,0.001020815],"category_scores_gemma":[0.0007187315,0.0002577232,0.0006219154,0.0001698518,0.0003973116,0.0004427755,0.0001425881,0.001315181,0.0003235136],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003969544,"about_ca_system_score_gemma":0.0005369431,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000405024,"about_ca_topic_score_gemma":0.0008598521,"domain_scores_codex":[0.9996502,0.0001816025,0.00002368488,0.0000442102,0.00005246153,0.00004775105],"domain_scores_gemma":[0.9993355,0.0001762367,0.0001276643,0.00005219194,0.00004386573,0.0002644852],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3983851,0.06007953,0.04520958,0.001162214,0.001918482,0.0007218256,0.000589471,0.004890792,0.09146561,0.0001439419,0.002741226,0.3926922],"study_design_scores_gemma":[0.2444747,0.6569971,0.07633998,0.00009185714,0.001110869,0.001464696,0.00009240876,0.003214238,0.01240606,0.0001087326,0.003665672,0.0000337225],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965333,0.00236738,0.0002107794,0.0001039232,0.00002676302,0.0001955051,0.0001142501,0.00001929802,0.0004288442],"genre_scores_gemma":[0.9965262,0.00142193,0.0006534505,0.0002317311,0.00008989315,0.0001813614,0.0005292383,0.000007235987,0.0003589045],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001124392,"threshold_uncertainty_score":0.005946457,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0600788206171172,"score_gpt":0.4065655712450807,"score_spread":0.3464867506279635,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}